University of Texas M.D. Anderson Cancer SPORE-Leukemia

德克萨斯大学安德森医学博士癌症孢子-白血病

• 批准号: 6786724
• 负责人: HAGOP KANTARJIAN
• 金额: $ 249.33万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-08-05 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6786724
• 关键词: acute myelogenous leukemia; clinical research; human subject

DESCRIPTION (provided by applicant): The University of Texas M.D. Anderson Cancer Center is proposing a Specialized Program of Research Excellence (SPORE) in Leukemia. The primary goal of this Leukemia SPORE is to cultivate and facilitate innovative and significant translational research in the biologic, genetic and clinical aspects of leukemia to improve understanding, therapy, and prognosis. The multidisciplinary group of investigators in the Leukemia SPORE will accomplish this goal through effective integration of laboratory, epidemiologic and clinical investigations. Such activity will further our understanding of genetic susceptibility and leukemogenic molecular processes in leukemia, leading to novel, molecularly targeted strategies in leukemia. The SPORE is designed with 6 research projects and 3 core resources, as well as programs for developmental research and career development. The research projects are designed to target specific areas important in leukemia. Project 1 - Epigenetics of Drug Resistance in Acute Leukemia -targets methylation for therapy in leukemia Project 2 -Adoptive Cellular Therapy of Myeloid Leukemia - targets the use of MPO-Specific Cytotoxic T Lymphocytes (CTL) to treat leukemia Project 3 - Concerted Blockade of Oncoprotein Activity - targets sequential DNA, RNA and oncoprotein blockage in leukemia Project 4 -PPAR-gamma Nuclear Transcription Factor: A Novel Target for Leukemia Therapy - targets PPAR-gamma expression for leukemia therapy Project 5 - Molecular Epidemiology of AML Risk and Progression - evaluates genetic-molecular susceptibilities to development of AML through studies of relevant detoxifying and carcinogenesis-promoting pathways Project 6 - Response of AML Patients to FLT3 Inhibitors - targets FLT3 ligand inhibition in leukemias expressing FLT3 mutations or internal tandem duplication (ITD) Core and other resources are: Core A - Administration, Core B - Pathology and Tissue, Core C - Biostatistics & Data Management, Developmental Research Program, and Career Development Program. Through this leukemia SPORE, our research team will make a significant impact on leukemia prognosis.

描述（由申请人提供）：德克萨斯大学 M.D. 安德森癌症中心正在提议一项白血病专业卓越研究计划 (SPORE)。 该白血病孢子的主要目标是培育和促进白血病生物学、遗传和临床方面的创新和重要转化研究，以改善对白血病的理解、治疗和预后。 白血病 SPORE 的多学科研究小组将通过实验室、流行病学和临床研究的有效整合来实现这一目标。 此类活动将进一步加深我们对白血病遗传易感性和白血病发生分子过程的理解，从而产生针对白血病的新颖的分子靶向策略。 SPORE 设计有 6 个研究项目和 3 个核心资源，以及发展研究和职业发展计划。 这些研究项目旨在针对白血病的重要特定领域。 项目 1 - 急性白血病耐药性的表观遗传学 - 靶向甲基化治疗白血病 项目 2 - 髓系白血病的过继细胞疗法 - 目标是使用 MPO 特异性细胞毒性 T 淋巴细胞 (CTL) 来治疗白血病 项目 3 - 协同阻断癌蛋白活性 - 针对白血病中的连续 DNA、RNA 和癌蛋白阻断 项目 4 -PPAR-γ 核转录因子：白血病治疗的新靶点 - 针对白血病治疗的 PPAR-γ 表达 项目 5 - AML 风险和进展的分子流行病学 - 通过研究相关的解毒和致癌促进途径，评估 AML 发展的遗传分子敏感性 项目 6 - AML 患者对 FLT3 抑制剂的反应 - 针对表达 FLT3 突变或内部串联重复 (ITD) 的白血病中的 FLT3 配体抑制 核心资源和其他资源包括：核心 A - 管理、核心 B - 病理学和组织、核心 C - 生物统计和数据管理、发展研究计划和职业发展计划。 通过这种白血病SPORE，我们的研究团队将对白血病的预后产生重大影响。